Αρχική World News No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients... World News No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection Από Ogkologos - 22 Ιουνίου, 2026 275 0 Facebook Twitter Google+ Pinterest WhatsApp Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... 1 Ιουλίου, 2025 Tailored Psychotherapy Eases Depression in People with Advanced Cancer 9 Αυγούστου, 2018 Health inequalities: Why do people smoke if they know it’s bad... 1 Απριλίου, 2022 Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas 10 Ιουλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Toripalimab Patient Guide in Bladder Cancer Now Available Also in Italian Disparities in Cancer Care Between Citizens and Refugees in Lebanon EMA Recommends Extension of Indications for Crizotinib